ArticleCureus2026
Identifying Predictors of Pathological Complete Response in Moroccan Patients With HER2-Positive Breast Cancer Treated With Neoadjuvant Therapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has significantly improved with the use of neoadjuvant chemotherapy combined with anti-HER2 therapy. Achieving pathological complete response (pCR) is commonly associated with favorable long-term outcomes. However, real-world data on predictive factors influencing pCR remain limited, particularly in Morocco and North Africa, where evidence is scarce. Generating region-specific evidence is therefore essential to complement findings from other populations. This study aimed to assess pCR rates and identify predictors of response in Moroccan patients with HER2-positive breast cancer treated with neoadjuvant systemic therapy. Methods We retrospectively included 203 patients with stage I-III HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, with or without pertuzumab, followed by surgery between October 2019 and April 2023. Predictors of pCR were assessed using logistic regression. Disease-free survival (DFS) was compared between patients achieving pCR and those without pCR using Cox proportional hazards regression analysis. Results Among 203 patients, 44.3% achieved pCR. Higher pCR rates were independently associated with hormone receptor-negative tumors (odds ratio (OR) = 2.20, 95% confidence interval (CI): 1.08-4.47), HER2 (score 3) status (OR = 4.80, 95% CI: 1.73-13.30), and the use of dual HER2 blockade (OR = 2.05, 95% CI: 1.03-4.07) compared with triple-positive tumors and HER2 (score 2) fluorescence in situ hybridization (FISH)-amplified tumors treated with trastuzumab alone. In contrast, lower pCR rates were observed in T3-T4 tumors (OR = 0.45, 95% CI: 0.23-0.92). After a median follow-up of 51.3 months, achieving pCR was significantly associated with improved DFS (HR = 0.07, 95% CI: 0.02-0.28; p < 0.001). Conclusions Tumor stage, hormone receptor status, HER2 expression, and neoadjuvant pertuzumab use were independently associated with pCR, emphasizing the importance of tailored neoadjuvant strategies in HER2-positive breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.